Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma.
Yuichiro DokiJaffer A AjaniKen KatoJianming XuLucjan WyrwiczSatoru MotoyamaTakashi OgataHisato KawakamiChih-Hung HsuAntoine AdenisFarid El HajbiMaria Di BartolomeoMaria I BraghiroliEva HoltvedSandra A OstoichHye R KimMasaki UenoWasat MansoorWen-Chi YangTianshu LiuJohn BridgewaterTomoki MakinoIoannis XynosXuan LiuMing LeiKaoru KondoApurva PatelJoseph GricarIan ChauYuko Kitagawanull nullPublished in: The New England journal of medicine (2022)
Both first-line treatment with nivolumab plus chemotherapy and first-line treatment with nivolumab plus ipilimumab resulted in significantly longer overall survival than chemotherapy alone in patients with advanced esophageal squamous-cell carcinoma, with no new safety signals identified. (Funded by Bristol Myers Squibb and Ono Pharmaceutical; CheckMate 648 ClinicalTrials.gov number, NCT03143153.).